Regulatory considerations for new stabilised poliovaccines
Related Experiment Video
Updated: Oct 2, 2026

In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
1Global Programme for Vaccines and Immunization, World Health Organization, Geneva, Switzerland.
Abstract:
As the least heat stable vaccine used by national immunization programmes, oral poliovaccine (OPV) is a target for improved stability. Dilution of OPV trivalent bulk vaccines meeting all international requirements in 87% deuterium oxide results in a significant stability increase of up to 1000-fold after incubation for one week at 45 degrees C. Regulatory considerations for a new formulation focus generally on the safety, potency and efficacy of the individual components (OPV and deuterium oxide) and ruling out any untoward and unexpected interactions between them. As the characteristics of OPV and deuterium oxide are well established, preclinical and clinica, data should address potential interactions. Because this stabilised vaccine is under development by two European manufacturers, initial regulatory discussions are being conducted with the European Medicines Evaluation Agency and its Committee on Proprietary Medicinal Products.
More Related Videos
Related Concept Videos
Clinically Relevant Drug Product Specifications: Methods of Establishment
Drug Product Stability
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Vaccine Production
Smallpox
Poliomyelitis

